Role of Met Axis in Head and Neck Cancer
Abstract
:1. Introduction
2. The Met Signaling Pathway and Functions
3. Regulation of Met Signaling Pathway
3.1. Positive Regulation
3.2. Negative Regulations of Met
3.2.1. Negative Regulation of Met by Protein Tyrosine Phosphatases (PTPs)
3.2.2. Negative Regulation of Met by Receptor Endocytosis
3.2.3. Other Negative Regulatory Mechanisms
4. The Role of Met in Cancer Progression and Metastasis
5. Met Axis in Head and Neck Cancer
5.1. Over-Activation of Met Axis in HNSCC
5.2. Met in HNSCC Progression
5.3. Met in Resistance to HNSCC Therapy
6. Targeting the MET Axis in HNSCC:
6.1. Cancer Drugs Targeting Met Pathway
6.2. Targeting Met Axis in HNSCC Cells and HNSCC Patients
7. Perspective and Conclusions
Acknowledgments
Conflicts of Interest
References
- Jemal, A.; Siegel, R.; Ward, E.; Hao, Y.; Xu, J.; Murray, T.; Thun, M.J. Cancer statistics, 2008. CA Cancer J. Clin. 2008, 58, 71–96. [Google Scholar] [CrossRef]
- Parkin, D.M.; Bray, F.; Ferlay, J.; Pisani, P. Global cancer statistics, 2002. CA Cancer J. Clin. 2005, 55, 74–108. [Google Scholar] [CrossRef]
- Argiris, A.; Eng, C. Epidemiology, staging, and screening of head and neck cancer. Cancer Treat. Res. 2003, 114, 15–60. [Google Scholar]
- D’Souza, G.; Kreimer, A.R.; Viscidi, R.; Pawlita, M.; Fakhry, C.; Koch, W.M.; Westra, W.H.; Gillison, M.L. Case-control study of human papillomavirus and oropharyngeal cancer. N. Engl. J. Med. 2007, 356, 1944–1956. [Google Scholar] [CrossRef]
- Haddad, R.I.; Shin, D.M. Recent advances in head and neck cancer. N. Engl. J. Med. 2008, 359, 1143–1154. [Google Scholar] [CrossRef]
- Lothaire, P.; de Azambuja, E.; Dequanter, D.; Lalami, Y.; Sotiriou, C.; Andry, G.; Castro, G., Jr.; Awada, A. Molecular markers of head and neck squamous cell carcinoma: Promising signs in need of prospective evaluation. Head Neck 2006, 28, 256–269. [Google Scholar] [CrossRef]
- Murdoch, D. Standard, and novel cytotoxic and molecular-targeted, therapies for hnscc: An evidence-based review. Curr. Opin. Oncol. 2007, 19, 216–221. [Google Scholar]
- Vermorken, J.B.; Mesia, R.; Rivera, F.; Remenar, E.; Kawecki, A.; Rottey, S.; Erfan, J.; Zabolotnyy, D.; Kienzer, H.R.; Cupissol, D.; et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N. Engl. J. Med. 2008, 359, 1116–1127. [Google Scholar] [CrossRef]
- Lau, P.C.; Chan, A.T. Novel therapeutic target for head and neck squamous cell carcinoma: Hgf-met signaling pathway. Anticancer Drugs 2011, 22, 665–673. [Google Scholar] [CrossRef]
- Nakamura, T.; Nishizawa, T.; Hagiya, M.; Seki, T.; Shimonishi, M.; Sugimura, A.; Tashiro, K.; Shimizu, S. Molecular cloning and expression of human hepatocyte growth factor. Nature 1989, 342, 440–443. [Google Scholar] [CrossRef]
- Birchmeier, C.; Birchmeier, W.; Gherardi, E.; vande Woude, G.F. Met, metastasis, motility and more. Nat. Rev. Mol. Cell Biol. 2003, 4, 915–925. [Google Scholar] [CrossRef]
- Soriano, J.V.; Pepper, M.S.; Nakamura, T.; Orci, L.; Montesano, R. Hepatocyte growth factor stimulates extensive development of branching duct-like structures by cloned mammary gland epithelial cells. J. Cell Sci. 1995, 108, 413–430. [Google Scholar]
- Weidner, K.M.; Sachs, M.; Birchmeier, W. The met receptor tyrosine kinase transduces motility, proliferation, and morphogenic signals of scatter factor/hepatocyte growth factor in epithelial cells. J. Cell Biol. 1993, 121, 145–154. [Google Scholar] [CrossRef]
- Gentile, A.; Trusolino, L.; Comoglio, P.M. The met tyrosine kinase receptor in development and cancer. Cancer Metastasis Rev. 2008, 27, 85–94. [Google Scholar] [CrossRef]
- Peschard, P.; Park, M. From tpr-met to met, tumorigenesis and tubes. Oncogene 2007, 26, 1276–1285. [Google Scholar] [CrossRef]
- Bottaro, D.P.; Rubin, J.S.; Faletto, D.L.; Chan, A.M.; Kmiecik, T.E.; vande Woude, G.F.; Aaronson, S.A. Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. Science 1991, 251, 802–804. [Google Scholar]
- Cooper, C.S.; Park, M.; Blair, D.G.; Tainsky, M.A.; Huebner, K.; Croce, C.M.; vande Woude, G.F. Molecular cloning of a new transforming gene from a chemically transformed human cell line. Nature 1984, 311, 29–33. [Google Scholar] [CrossRef]
- Trusolino, L.; Bertotti, A.; Comoglio, P.M. Met signalling: Principles and functions in development, organ regeneration and cancer. Nat. Rev. Mol. Cell Biol. 2010, 11, 834–848. [Google Scholar] [CrossRef]
- Ma, P.C.; Maulik, G.; Christensen, J.; Salgia, R. C-met: Structure, functions and potential for therapeutic inhibition. Cancer Metastasis Rev. 2003, 22, 309–325. [Google Scholar] [CrossRef]
- Peruzzi, B.; Bottaro, D.P. Targeting the c-met signaling pathway in cancer. Clin. Cancer Res. 2006, 12, 3657–3660. [Google Scholar] [CrossRef]
- Rubin, J.S.; Bottaro, D.P.; Aaronson, S.A. Hepatocyte growth factor/scatter factor and its receptor, the c-met proto-oncogene product. Biochim. Biophys. Acta 1993, 1155, 357–371. [Google Scholar]
- Stuart, K.A.; Riordan, S.M.; Lidder, S.; Crostella, L.; Williams, R.; Skouteris, G.G. Hepatocyte growth factor/scatter factor-induced intracellular signalling. Int. J. Exp. Pathol. 2000, 81, 17–30. [Google Scholar] [CrossRef]
- Komada, M.; Kitamura, N. The cell dissociation and motility triggered by scatter factor/hepatocyte growth factor are mediated through the cytoplasmic domain of the c-met receptor. Oncogene 1993, 8, 2381–2390. [Google Scholar]
- Naldini, L.; Vigna, E.; Ferracini, R.; Longati, P.; Gandino, L.; Prat, M.; Comoglio, P.M. The tyrosine kinase encoded by the met proto-oncogene is activated by autophosphorylation. Mol. Cell Biol. 1991, 11, 1793–1803. [Google Scholar]
- Bolanos-Garcia, V.M. Met meet adaptors: Functional and structural implications in downstream signalling mediated by the met receptor. Mol. Cell Biochem 2005, 276, 149–157. [Google Scholar] [CrossRef]
- Ferracini, R.; Longati, P.; Naldini, L.; Vigna, E.; Comoglio, P.M. Identification of the major autophosphorylation site of the met/hepatocyte growth factor receptor tyrosine kinase. J. Biol. Chem. 1991, 266, 19558–19564. [Google Scholar]
- Longati, P.; Bardelli, A.; Ponzetto, C.; Naldini, L.; Comoglio, P.M. Tyrosines1234–1235 are critical for activation of the tyrosine kinase encoded by the met proto-oncogene (hgf receptor). Oncogene 1994, 9, 49–57. [Google Scholar]
- Fixman, E.D.; Naujokas, M.A.; Rodrigues, G.A.; Moran, M.F.; Park, M. Efficient cell transformation by the tpr-met oncoprotein is dependent upon tyrosine 489 in the carboxy-terminus. Oncogene 1995, 10, 237–249. [Google Scholar]
- Ponzetto, C.; Bardelli, A.; Zhen, Z.; Maina, F.; dalla Zonca, P.; Giordano, S.; Graziani, A.; Panayotou, G.; Comoglio, P.M. A multifunctional docking site mediates signaling and transformation by the hepatocyte growth factor/scatter factor receptor family. Cell 1994, 77, 261–271. [Google Scholar] [CrossRef]
- Zhu, H.; Naujokas, M.A.; Fixman, E.D.; Torossian, K.; Park, M. Tyrosine 1356 in the carboxyl-terminal tail of the hgf/sf receptor is essential for the transduction of signals for cell motility and morphogenesis. J. Biol. Chem. 1994, 269, 29943–29948. [Google Scholar]
- Schaeper, U.; Gehring, N.H.; Fuchs, K.P.; Sachs, M.; Kempkes, B.; Birchmeier, W. Coupling of gab1 to c-met, grb2, and shp2 mediates biological responses. J. Cell Biol. 2000, 149, 1419–1432. [Google Scholar] [CrossRef]
- Gual, P.; Giordano, S.; Williams, T.A.; Rocchi, S.; van Obberghen, E.; Comoglio, P.M. Sustained recruitment of phospholipase c-gamma to gab1 is required for hgf-induced branching tubulogenesis. Oncogene 2000, 19, 1509–1518. [Google Scholar] [CrossRef]
- Ponta, H.; Sherman, L.; Herrlich, P.A. Cd44: From adhesion molecules to signalling regulators. Nat. Rev. Mol. Cell Biol 2003, 4, 33–45. [Google Scholar] [CrossRef]
- Orian-Rousseau, V.; Chen, L.; Sleeman, J.P.; Herrlich, P.; Ponta, H. Cd44 is required for two consecutive steps in hgf/c-met signaling. Genes Dev. 2002, 16, 3074–3086. [Google Scholar] [CrossRef]
- Olaku, V.; Matzke, A.; Mitchell, C.; Hasenauer, S.; Sakkaravarthi, A.; Pace, G.; Ponta, H.; Orian-Rousseau, V. C-met recruits icam-1 as a coreceptor to compensate for the loss of cd44 in cd44 null mice. Mol. Biol. Cell 2011, 22, 2777–2786. [Google Scholar] [CrossRef]
- Orian-Rousseau, V.; Morrison, H.; Matzke, A.; Kastilan, T.; Pace, G.; Herrlich, P.; Ponta, H. Hepatocyte growth factor-induced ras activation requires erm proteins linked to both cd44v6 and f-actin. Mol. Biol. Cell 2007, 18, 76–83. [Google Scholar]
- Singleton, P.A.; Salgia, R.; Moreno-Vinasco, L.; Moitra, J.; Sammani, S.; Mirzapoiazova, T.; Garcia, J.G. Cd44 regulates hepatocyte growth factor-mediated vascular integrity. Role of c-met, tiam1/rac1, dynamin 2, and cortactin. J. Biol. Chem. 2007, 282, 30643–30657. [Google Scholar] [CrossRef]
- Raper, J.A. Semaphorins and their receptors in vertebrates and invertebrates. Curr. Opin. Neurobiol. 2000, 10, 88–94. [Google Scholar] [CrossRef]
- Driessens, M.H.; Hu, H.; Nobes, C.D.; Self, A.; Jordens, I.; Goodman, C.S.; Hall, A. Plexin-b semaphorin receptors interact directly with active rac and regulate the actin cytoskeleton by activating rho. Curr. Biol. 2001, 11, 339–344. [Google Scholar] [CrossRef]
- Perrot, V.; Vazquez-Prado, J.; Gutkind, J.S. Plexin b regulates rho through the guanine nucleotide exchange factors leukemia-associated rho gef (larg) and pdz-rhogef. J. Biol. Chem. 2002, 277, 43115–43120. [Google Scholar]
- Vikis, H.G.; Li, W.; He, Z.; Guan, K.L. The semaphorin receptor plexin-b1 specifically interacts with active rac in a ligand-dependent manner. Proc. Natl. Acad. Sci. USA 2000, 97, 12457–12462. [Google Scholar] [CrossRef]
- Conrotto, P.; Corso, S.; Gamberini, S.; Comoglio, P.M.; Giordano, S. Interplay between scatter factor receptors and b plexins controls invasive growth. Oncogene 2004, 23, 5131–5137. [Google Scholar]
- Hu, B.; Guo, P.; Bar-Joseph, I.; Imanishi, Y.; Jarzynka, M.J.; Bogler, O.; Mikkelsen, T.; Hirose, T.; Nishikawa, R.; Cheng, S.Y. Neuropilin-1 promotes human glioma progression through potentiating the activity of the hgf/sf autocrine pathway. Oncogene 2007, 26, 5577–5586. [Google Scholar] [CrossRef]
- Bertotti, A.; Comoglio, P.M.; Trusolino, L. Beta4 integrin is a transforming molecule that unleashes met tyrosine kinase tumorigenesis. Cancer Res. 2005, 65, 10674–10679. [Google Scholar] [CrossRef]
- Trusolino, L.; Bertotti, A.; Comoglio, P.M. A signaling adapter function for alpha6beta4 integrin in the control of hgf-dependent invasive growth. Cell 2001, 107, 643–654. [Google Scholar] [CrossRef]
- Mainiero, F.; Murgia, C.; Wary, K.K.; Curatola, A.M.; Pepe, A.; Blumemberg, M.; Westwick, J.K.; Der, C.J.; Giancotti, F.G. The coupling of alpha6beta4 integrin to ras-map kinase pathways mediated by shc controls keratinocyte proliferation. EMBO J. 1997, 16, 2365–2375. [Google Scholar] [CrossRef]
- Lai, A.Z.; Abella, J.V.; Park, M. Crosstalk in met receptor oncogenesis. Trends Cell Biol. 2009, 19, 542–551. [Google Scholar] [CrossRef]
- Jo, M.; Stolz, D.B.; Esplen, J.E.; Dorko, K.; Michalopoulos, G.K.; Strom, S.C. Cross-talk between epidermal growth factor receptor and c-met signal pathways in transformed cells. J. Biol. Chem. 2000, 275, 8806–8811. [Google Scholar]
- Follenzi, A.; Bakovic, S.; Gual, P.; Stella, M.C.; Longati, P.; Comoglio, P.M. Cross-talk between the proto-oncogenes met and ron. Oncogene 2000, 19, 3041–3049. [Google Scholar] [CrossRef]
- Fischer, O.M.; Giordano, S.; Comoglio, P.M.; Ullrich, A. Reactive oxygen species mediate met receptor transactivation by g protein-coupled receptors and the epidermal growth factor receptor in human carcinoma cells. J. Biol. Chem. 2004, 279, 28970–28978. [Google Scholar] [CrossRef]
- Palka, H.L.; Park, M.; Tonks, N.K. Hepatocyte growth factor receptor tyrosine kinase met is a substrate of the receptor protein-tyrosine phosphatase dep-1. J. Biol. Chem. 2003, 278, 5728–5735. [Google Scholar] [CrossRef]
- Machide, M.; Hashigasako, A.; Matsumoto, K.; Nakamura, T. Contact inhibition of hepatocyte growth regulated by functional association of the c-met/hepatocyte growth factor receptor and lar protein-tyrosine phosphatase. J. Biol. Chem. 2006, 281, 8765–8772. [Google Scholar] [CrossRef]
- Sangwan, V.; Paliouras, G.N.; Abella, J.V.; Dube, N.; Monast, A.; Tremblay, M.L.; Park, M. Regulation of the met receptor-tyrosine kinase by the protein-tyrosine phosphatase 1b and t-cell phosphatase. J. Biol. Chem. 2008, 283, 34374–34383. [Google Scholar]
- Xu, Y.; Xia, W.; Baker, D.; Zhou, J.; Cha, H.C.; Voorhees, J.J.; Fisher, G.J. Receptor-type protein tyrosine phosphatase beta (rptp-beta) directly dephosphorylates and regulates hepatocyte growth factor receptor (hgfr/met) function. J. Biol. Chem. 2011, 286, 15980–15988. [Google Scholar]
- Xu, Y.; Zhou, J.; Carey, T.E.; McHugh, J.B.; Voorhees, J.J.; Fisher, G.J. Receptor-type protein tyrosine phosphatase beta regulates met phosphorylation and function in head and neck squamous cell carcinoma. Neoplasia 2012, 14, 1015–1022. [Google Scholar]
- Horiguchi, N.; Takayama, H.; Toyoda, M.; Otsuka, T.; Fukusato, T.; Merlino, G.; Takagi, H.; Mori, M. Hepatocyte growth factor promotes hepatocarcinogenesis through c-met autocrine activation and enhanced angiogenesis in transgenic mice treated with diethylnitrosamine. Oncogene 2002, 21, 1791–1799. [Google Scholar] [CrossRef]
- Otsuka, T.; Takayama, H.; Sharp, R.; Celli, G.; LaRochelle, W.J.; Bottaro, D.P.; Ellmore, N.; Vieira, W.; Owens, J.W.; Anver, M.; et al. C-met autocrine activation induces development of malignant melanoma and acquisition of the metastatic phenotype. Cancer Res. 1998, 58, 5157–5167. [Google Scholar]
- Carter, S.; Urbe, S.; Clague, M.J. The met receptor degradation pathway: Requirement for lys48-linked polyubiquitin independent of proteasome activity. J. Biol. Chem. 2004, 279, 52835–52839. [Google Scholar] [CrossRef]
- Peschard, P.; Fournier, T.M.; Lamorte, L.; Naujokas, M.A.; Band, H.; Langdon, W.Y.; Park, M. Mutation of the c-cbl tkb domain binding site on the met receptor tyrosine kinase converts it into a transforming protein. Mol. Cell 2001, 8, 995–1004. [Google Scholar] [CrossRef]
- Petrelli, A.; Gilestro, G.F.; Lanzardo, S.; Comoglio, P.M.; Migone, N.; Giordano, S. The endophilin-cin85-cbl complex mediates ligand-dependent downregulation of c-met. Nature 2002, 416, 187–190. [Google Scholar] [CrossRef]
- Foveau, B.; Ancot, F.; Leroy, C.; Petrelli, A.; Reiss, K.; Vingtdeux, V.; Giordano, S.; Fafeur, V.; Tulasne, D. Down-regulation of the met receptor tyrosine kinase by presenilin-dependent regulated intramembrane proteolysis. Mol. Biol. Cell 2009, 20, 2495–2507. [Google Scholar] [CrossRef]
- Shattuck, D.L.; Miller, J.K.; Laederich, M.; Funes, M.; Petersen, H.; Carraway, K.L., 3rd; Sweeney, C. Lrig1 is a novel negative regulator of the met receptor and opposes met and her2 synergy. Mol. Cell Biol. 2007, 27, 1934–1946. [Google Scholar] [CrossRef]
- Garofalo, M.; Croce, C.M. Micrornas: Master regulators as potential therapeutics in cancer. Annu. Rev. Pharmacol. Toxicol. 2011, 51, 25–43. [Google Scholar] [CrossRef]
- Hu, G.; Chen, D.; Li, X.; Yang, K.; Wang, H.; Wu, W. Mir-133b regulates the met proto-oncogene and inhibits the growth of colorectal cancer cells in vitro and in vivo. Cancer Biol. Ther. 2010, 10, 190–197. [Google Scholar] [CrossRef]
- Kim, S.; Lee, U.J.; Kim, M.N.; Lee, E.J.; Kim, J.Y.; Lee, M.Y.; Choung, S.; Kim, Y.J.; Choi, Y.C. Microrna mir-199a* regulates the met proto-oncogene and the downstream extracellular signal-regulated kinase 2 (erk2). J. Biol. Chem. 2008, 283, 18158–18166. [Google Scholar]
- Migliore, C.; Petrelli, A.; Ghiso, E.; Corso, S.; Capparuccia, L.; Eramo, A.; Comoglio, P.M.; Giordano, S. Micrornas impair met-mediated invasive growth. Cancer Res. 2008, 68, 10128–10136. [Google Scholar] [CrossRef]
- Salvi, A.; Sabelli, C.; Moncini, S.; Venturin, M.; Arici, B.; Riva, P.; Portolani, N.; Giulini, S.M.; de Petro, G.; Barlati, S. Microrna-23b mediates urokinase and c-met downmodulation and a decreased migration of human hepatocellular carcinoma cells. FEBS J. 2009, 276, 2966–2982. [Google Scholar] [CrossRef]
- Lesko, E.; Majka, M. The biological role of hgf-met axis in tumor growth and development of metastasis. Front. Biosci. 2008, 13, 1271–1280. [Google Scholar] [CrossRef]
- Gherardi, E.; Birchmeier, W.; Birchmeier, C.; vande Woude, G. Targeting met in cancer: Rationale and progress. Nat. Rev. Cancer 2012, 12, 89–103. [Google Scholar]
- Ma, P.C.; Tretiakova, M.S.; MacKinnon, A.C.; Ramnath, N.; Johnson, C.; Dietrich, S.; Seiwert, T.; Christensen, J.G.; Jagadeeswaran, R.; Krausz, T.; et al. Expression and mutational analysis of met in human solid cancers. Genes Chromosomes Cancer 2008, 47, 1025–1037. [Google Scholar] [CrossRef]
- Samame Perez-Vargas, J.C.; Biondani, P.; Maggi, C.; Gariboldi, M.; Gloghini, A.; Inno, A.; Volpi, C.C.; Gualeni, A.V.; di Bartolomeo, M.; de Braud, F.; et al. Role of cmet in the development and progression of colorectal cancer. Int. J. Mol. Sci. 2013, 14, 18056–18077. [Google Scholar] [CrossRef]
- Park, M.; Dean, M.; Kaul, K.; Braun, M.J.; Gonda, M.A.; vande Woude, G. Sequence of met protooncogene cdna has features characteristic of the tyrosine kinase family of growth-factor receptors. Proc. Natl. Acad. Sci. USA 1987, 84, 6379–6383. [Google Scholar] [CrossRef]
- Yu, J.; Miehlke, S.; Ebert, M.P.; Hoffmann, J.; Breidert, M.; Alpen, B.; Starzynska, T.; Stolte, M.; Malfertheiner, P.; Bayerdorffer, E. Frequency of tpr-met rearrangement in patients with gastric carcinoma and in first-degree relatives. Cancer 2000, 88, 1801–1806. [Google Scholar] [CrossRef]
- Trusolino, L.; Comoglio, P.M. Scatter-factor and semaphorin receptors: Cell signalling for invasive growth. Nat. Rev. Cancer 2002, 2, 289–300. [Google Scholar] [CrossRef]
- Jeffers, M.; Rong, S.; Woude, G.F. Hepatocyte growth factor/scatter factor-met signaling in tumorigenicity and invasion/metastasis. J. Mol. Med. 1996, 74, 505–513. [Google Scholar] [CrossRef]
- Mazzone, M.; Comoglio, P.M. The met pathway: Master switch and drug target in cancer progression. FASEB J. 2006, 20, 1611–1621. [Google Scholar] [CrossRef]
- Engelman, J.A.; Zejnullahu, K.; Mitsudomi, T.; Song, Y.; Hyland, C.; Park, J.O.; Lindeman, N.; Gale, C.M.; Zhao, X.; Christensen, J.; et al. Met amplification leads to gefitinib resistance in lung cancer by activating erbb3 signaling. Science 2007, 316, 1039–1043. [Google Scholar] [CrossRef]
- Chen, G.; Noor, A.; Kronenberger, P.; Teugels, E.; Umelo, I.A.; de Greve, J. Synergistic effect of afatinib with su11274 in non-small cell lung cancer cells resistant to gefitinib or erlotinib. PLoS One 2013, 8, e59708. [Google Scholar]
- Seiwert, T.Y.; Jagadeeswaran, R.; Faoro, L.; Janamanchi, V.; Nallasura, V.; El Dinali, M.; Yala, S.; Kanteti, R.; Cohen, E.E.; Lingen, M.W.; et al. The met receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. Cancer Res. 2009, 69, 3021–3031. [Google Scholar] [CrossRef]
- Zhang, Y.W.; Staal, B.; Essenburg, C.; Lewis, S.; Kaufman, D.; vande Woude, G.F. Strengthening context-dependent anticancer effects on non-small cell lung carcinoma by inhibition of both met and egfr. Mol. Cancer Ther. 2013, 12, 1429–1441. [Google Scholar] [CrossRef]
- Chen, Y.S.; Wang, J.T.; Chang, Y.F.; Liu, B.Y.; Wang, Y.P.; Sun, A.; Chiang, C.P. Expression of hepatocyte growth factor and c-met protein is significantly associated with the progression of oral squamous cell carcinoma in Taiwan. J. Oral. Pathol. Med. 2004, 33, 209–217. [Google Scholar] [CrossRef]
- Kim, C.H.; Moon, S.K.; Bae, J.H.; Lee, J.H.; Han, J.H.; Kim, K.; Choi, E.C. Expression of hepatocyte growth factor and c-met in hypopharyngeal squamous cell carcinoma. Acta Otolaryngol. 2006, 126, 88–94. [Google Scholar] [CrossRef]
- Marshall, D.D.; Kornberg, L.J. Overexpression of scatter factor and its receptor (c-met) in oral squamous cell carcinoma. Laryngoscope 1998, 108, 1413–1417. [Google Scholar] [CrossRef]
- Sawatsubashi, M.; Sasatomi, E.; Mizokami, H.; Tokunaga, O.; Shin, T. Expression of c-met in laryngeal carcinoma. Virchows Arch. 1998, 432, 331–335. [Google Scholar] [CrossRef]
- Knowles, L.M.; Stabile, L.P.; Egloff, A.M.; Rothstein, M.E.; Thomas, S.M.; Gubish, C.T.; Lerner, E.C.; Seethala, R.R.; Suzuki, S.; Quesnelle, K.M.; et al. Hgf and c-met participate in paracrine tumorigenic pathways in head and neck squamous cell cancer. Clin. Cancer Res. 2009, 15, 3740–3750. [Google Scholar] [CrossRef]
- Cortesina, G.; Martone, T.; Galeazzi, E.; Olivero, M.; de Stefani, A.; Bussi, M.; Valente, G.; Comoglio, P.M.; di Renzo, M.F. Staging of head and neck squamous cell carcinoma using the met oncogene product as marker of tumor cells in lymph node metastases. Int. J. Cancer 2000, 89, 286–292. [Google Scholar] [CrossRef]
- Galeazzi, E.; Olivero, M.; Gervasio, F.C.; de Stefani, A.; Valente, G.; Comoglio, P.M.; di Renzo, M.F.; Cortesina, G. Detection of met oncogene/hepatocyte growth factor receptor in lymph node metastases from head and neck squamous cell carcinomas. Eur. Arch. Otorhinolaryngol. 1997, 254, S138–S143. [Google Scholar] [CrossRef]
- Lo Muzio, L.; Leonardi, R.; Mignogna, M.D.; Pannone, G.; Rubini, C.; Pieramici, T.; Trevisiol, L.; Ferrari, F.; Serpico, R.; Testa, N.; et al. Scatter factor receptor (c-met) as possible prognostic factor in patients with oral squamous cell carcinoma. Anticancer Res. 2004, 24, 1063–1069. [Google Scholar]
- Tuynman, J.B.; Lagarde, S.M.; Ten Kate, F.J.; Richel, D.J.; van Lanschot, J.J. Met expression is an independent prognostic risk factor in patients with oesophageal adenocarcinoma. Br. J. Cancer 2008, 98, 1102–1108. [Google Scholar] [CrossRef]
- Aebersold, D.M.; Kollar, A.; Beer, K.T.; Laissue, J.; Greiner, R.H.; Djonov, V. Involvement of the hepatocyte growth factor/scatter factor receptor c-met and of bcl-xl in the resistance of oropharyngeal cancer to ionizing radiation. Int. J. Cancer 2001, 96, 41–54. [Google Scholar] [CrossRef]
- Akervall, J.; Guo, X.; Qian, C.N.; Schoumans, J.; Leeser, B.; Kort, E.; Cole, A.; Resau, J.; Bradford, C.; Carey, T.; et al. Genetic and expression profiles of squamous cell carcinoma of the head and neck correlate with cisplatin sensitivity and resistance in cell lines and patients. Clin. Cancer Res. 2004, 10, 8204–8213. [Google Scholar] [CrossRef]
- Ren, Y.; Cao, B.; Law, S.; Xie, Y.; Lee, P.Y.; Cheung, L.; Chen, Y.; Huang, X.; Chan, H.M.; Zhao, P.; et al. Hepatocyte growth factor promotes cancer cell migration and angiogenic factors expression: A prognostic marker of human esophageal squamous cell carcinomas. Clin. Cancer Res. 2005, 11, 6190–6197. [Google Scholar] [CrossRef]
- Uchida, D.; Kawamata, H.; Omotehara, F.; Nakashiro, K.; Kimura-Yanagawa, T.; Hino, S.; Begum, N.M.; Hoque, M.O.; Yoshida, H.; Sato, M.; et al. Role of hgf/c-met system in invasion and metastasis of oral squamous cell carcinoma cells in vitro and its clinical significance. Int. J. Cancer 2001, 93, 489–496. [Google Scholar] [CrossRef]
- Hanzawa, M.; Shindoh, M.; Higashino, F.; Yasuda, M.; Inoue, N.; Hida, K.; Ono, M.; Kohgo, T.; Nakamura, M.; Notani, K.; et al. Hepatocyte growth factor upregulates e1af that induces oral squamous cell carcinoma cell invasion by activating matrix metalloproteinase genes. Carcinogenesis 2000, 21, 1079–1085. [Google Scholar] [CrossRef]
- Di Renzo, M.F.; Olivero, M.; Martone, T.; Maffe, A.; Maggiora, P.; Stefani, A.D.; Valente, G.; Giordano, S.; Cortesina, G.; Comoglio, P.M. Somatic mutations of the met oncogene are selected during metastatic spread of human hnsc carcinomas. Oncogene 2000, 19, 1547–1555. [Google Scholar] [CrossRef]
- Frixen, U.H.; Behrens, J.; Sachs, M.; Eberle, G.; Voss, B.; Warda, A.; Lochner, D.; Birchmeier, W. E-cadherin-mediated cell-cell adhesion prevents invasiveness of human carcinoma cells. J. Cell Biol. 1991, 113, 173–185. [Google Scholar]
- Kim, C.H.; Kim, J.; Kahng, H.; Choi, E.C. Change of e-cadherin by hepatocyte growth factor and effects on the prognosis of hypopharyngeal carcinoma. Ann. Surg. Oncol. 2007, 14, 1565–1574. [Google Scholar] [CrossRef]
- Grotegut, S.; von Schweinitz, D.; Christofori, G.; Lehembre, F. Hepatocyte growth factor induces cell scattering through mapk/egr-1-mediated upregulation of snail. EMBO J. 2006, 25, 3534–3545. [Google Scholar] [CrossRef]
- Cano, A.; Perez-Moreno, M.A.; Rodrigo, I.; Locascio, A.; Blanco, M.J.; del Barrio, M.G.; Portillo, F.; Nieto, M.A. The transcription factor snail controls epithelial-mesenchymal transitions by repressing e-cadherin expression. Nat. Cell Biol. 2000, 2, 76–83. [Google Scholar] [CrossRef]
- Yokoyama, K.; Kamata, N.; Fujimoto, R.; Tsutsumi, S.; Tomonari, M.; Taki, M.; Hosokawa, H.; Nagayama, M. Increased invasion and matrix metalloproteinase-2 expression by snail-induced mesenchymal transition in squamous cell carcinomas. Int. J. Oncol. 2003, 22, 891–898. [Google Scholar]
- Yokoyama, K.; Kamata, N.; Hayashi, E.; Hoteiya, T.; Ueda, N.; Fujimoto, R.; Nagayama, M. Reverse correlation of e-cadherin and snail expression in oral squamous cell carcinoma cells in vitro. Oral. Oncol. 2001, 37, 65–71. [Google Scholar]
- Lim, Y.C.; Park, H.Y.; Hwang, H.S.; Kang, S.U.; Pyun, J.H.; Lee, M.H.; Choi, E.C.; Kim, C.H. (−)-epigallocatechin-3-gallate (egcg) inhibits hgf-induced invasion and metastasis in hypopharyngeal carcinoma cells. Cancer Lett. 2008, 271, 140–152. [Google Scholar] [CrossRef]
- Kitajo, H.; Shibata, T.; Nagayasu, H.; Kawano, T.; Hamada, J.; Yamashita, T.; Arisue, M. Rho regulates the hepatocyte growth factor/scatter factor-stimulated cell motility of human oral squamous cell carcinoma cells. Oncol. Rep. 2003, 10, 1351–1356. [Google Scholar]
- Matsumoto, K.; Nakamura, T.; Kramer, R.H. Hepatocyte growth factor/scatter factor induces tyrosine phosphorylation of focal adhesion kinase (p125fak) and promotes migration and invasion by oral squamous cell carcinoma cells. J. Biol. Chem. 1994, 269, 31807–31813. [Google Scholar]
- Zeng, Q.; Chen, S.; You, Z.; Yang, F.; Carey, T.E.; Saims, D.; Wang, C.Y. Hepatocyte growth factor inhibits anoikis in head and neck squamous cell carcinoma cells by activation of erk and akt signaling independent of nfkappa b. J. Biol. Chem. 2002, 277, 25203–25208. [Google Scholar]
- Dong, G.; Chen, Z.; Li, Z.Y.; Yeh, N.T.; Bancroft, C.C.; van Waes, C. Hepatocyte growth factor/scatter factor-induced activation of mek and pi3k signal pathways contributes to expression of proangiogenic cytokines interleukin-8 and vascular endothelial growth factor in head and neck squamous cell carcinoma. Cancer Res. 2001, 61, 5911–5918. [Google Scholar]
- Dong, G.; Lee, T.L.; Yeh, N.T.; Geoghegan, J.; van Waes, C.; Chen, Z. Metastatic squamous cell carcinoma cells that overexpress c-met exhibit enhanced angiogenesis factor expression, scattering and metastasis in response to hepatocyte growth factor. Oncogene 2004, 23, 6199–6208. [Google Scholar] [CrossRef]
- Sun, S.; Wang, Z. Head neck squamous cell carcinoma c-met(+) cells display cancer stem cell properties and are responsible for cisplatin-resistance and metastasis. Int. J. Cancer 2011, 129, 2337–2348. [Google Scholar] [CrossRef]
- Rubin Grandis, J.; Melhem, M.F.; Barnes, E.L.; Tweardy, D.J. Quantitative immunohistochemical analysis of transforming growth factor-alpha and epidermal growth factor receptor in patients with squamous cell carcinoma of the head and neck. Cancer 1996, 78, 1284–1292. [Google Scholar] [CrossRef]
- Schmitz, S.; Machiels, J.P. Molecular biology of squamous cell carcinoma of the head and neck: Relevance and therapeutic implications. Expert Rev. Anticancer Ther. 2010, 10, 1471–1484. [Google Scholar] [CrossRef]
- Egloff, A.M.; Grandis, J.R. Targeting epidermal growth factor receptor and src pathways in head and neck cancer. Semin. Oncol. 2008, 35, 286–297. [Google Scholar] [CrossRef]
- Breindel, J.L.; Haskins, J.W.; Cowell, E.P.; Zhao, M.; Nguyen, D.X.; Stern, D.F. Egf receptor activates met through mapk to enhance non-small cell lung carcinoma invasion and brain metastasis. Cancer Res. 2013, 73, 5053–5065. [Google Scholar] [CrossRef]
- Burtness, B.; Bauman, J.E.; Galloway, T. Novel targets in hpv-negative head and neck cancer: Overcoming resistance to egfr inhibition. Lancet Oncol. 2013, 14, e302–e309. [Google Scholar] [CrossRef]
- Timpson, P.; Wilson, A.S.; Lehrbach, G.M.; Sutherland, R.L.; Musgrove, E.A.; Daly, R.J. Aberrant expression of cortactin in head and neck squamous cell carcinoma cells is associated with enhanced cell proliferation and resistance to the epidermal growth factor receptor inhibitor gefitinib. Cancer Res. 2007, 67, 9304–9314. [Google Scholar] [CrossRef]
- Stabile, L.P.; He, G.; Lui, V.W.; Thomas, S.; Henry, C.; Gubish, C.T.; Joyce, S.; Quesnelle, K.M.; Siegfried, J.M.; Grandis, J.R. C-src activation mediates erlotinib resistance in head and neck cancer by stimulating c-met. Clin. Cancer Res. 2013, 19, 380–392. [Google Scholar] [CrossRef]
- Date, K.; Matsumoto, K.; Shimura, H.; Tanaka, M.; Nakamura, T. Hgf/nk4 is a specific antagonist for pleiotrophic actions of hepatocyte growth factor. FEBS Lett. 1997, 420, 1–6. [Google Scholar] [CrossRef]
- Matsumoto, K.; Nakamura, T. Mechanisms and significance of bifunctional nk4 in cancer treatment. Biochem. Biophys. Res. Commun. 2005, 333, 316–327. [Google Scholar] [CrossRef]
- Mizuno, S.; Nakamura, T. Hgf-met cascade, a key target for inhibiting cancer metastasis: The impact of nk4 discovery on cancer biology and therapeutics. Int. J. Mol. Sci. 2013, 14, 888–919. [Google Scholar] [CrossRef]
- Burgess, T.; Coxon, A.; Meyer, S.; Sun, J.; Rex, K.; Tsuruda, T.; Chen, Q.; Ho, S.Y.; Li, L.; Kaufman, S.; et al. Fully human monoclonal antibodies to hepatocyte growth factor with therapeutic potential against hepatocyte growth factor/c-met-dependent human tumors. Cancer Res. 2006, 66, 1721–1729. [Google Scholar] [CrossRef]
- Kakkar, T.; Ma, M.; Zhuang, Y.; Patton, A.; Hu, Z.; Mounho, B. Pharmacokinetics and safety of a fully human hepatocyte growth factor antibody, amg 102, in cynomolgus monkeys. Pharm. Res. 2007, 24, 1910–1918. [Google Scholar] [CrossRef]
- Rosen, P.J.; Sweeney, C.J.; Park, D.J.; Beaupre, D.M.; Deng, H.; Leitch, I.M.; Shubhakar, P.; Zhu, M.; Oliner, K.S.; Anderson, A.; et al. A phase ib study of amg 102 in combination with bevacizumab or motesanib in patients with advanced solid tumors. Clin. Cancer Res. 2010, 16, 2677–2687. [Google Scholar] [CrossRef]
- Wen, P.Y.; Schiff, D.; Cloughesy, T.F.; Raizer, J.J.; Laterra, J.; Smitt, M.; Wolf, M.; Oliner, K.S.; Anderson, A.; Zhu, M.; et al. A phase ii study evaluating the efficacy and safety of amg 102 (rilotumumab) in patients with recurrent glioblastoma. Neurooncology 2011, 13, 437–446. [Google Scholar]
- Scagliotti, G.V.; Novello, S.; von Pawel, J. The emerging role of met/hgf inhibitors in oncology. Cancer Treat. Rev. 2013, 39, 793–801. [Google Scholar] [CrossRef]
- Jin, H.; Yang, R.; Zheng, Z.; Romero, M.; Ross, J.; Bou-Reslan, H.; Carano, R.A.; Kasman, I.; Mai, E.; Young, J.; et al. Metmab, the one-armed 5d5 anti-c-met antibody, inhibits orthotopic pancreatic tumor growth and improves survival. Cancer Res. 2008, 68, 4360–4368. [Google Scholar] [CrossRef]
- Martens, T.; Schmidt, N.O.; Eckerich, C.; Fillbrandt, R.; Merchant, M.; Schwall, R.; Westphal, M.; Lamszus, K. A novel one-armed anti-c-met antibody inhibits glioblastoma growth in vivo. Clin. Cancer Res. 2006, 12, 6144–6152. [Google Scholar] [CrossRef]
- Munshi, N.; Jeay, S.; Li, Y.; Chen, C.R.; France, D.S.; Ashwell, M.A.; Hill, J.; Moussa, M.M.; Leggett, D.S.; Li, C.J. Arq 197, a novel and selective inhibitor of the human c-met receptor tyrosine kinase with antitumor activity. Mol. Cancer Ther. 2010, 9, 1544–1553. [Google Scholar] [CrossRef]
- Bagai, R.; Fan, W.; Ma, P.C. Arq-197, an oral small-molecule inhibitor of c-met for the treatment of solid tumors. IDrugs 2010, 13, 404–414. [Google Scholar]
- Eder, J.P.; vande Woude, G.F.; Boerner, S.A.; LoRusso, P.M. Novel therapeutic inhibitors of the c-met signaling pathway in cancer. Clin. Cancer Res. 2009, 15, 2207–2214. [Google Scholar] [CrossRef]
- Christensen, J.G.; Zou, H.Y.; Arango, M.E.; Li, Q.; Lee, J.H.; McDonnell, S.R.; Yamazaki, S.; Alton, G.R.; Mroczkowski, B.; Los, G. Cytoreductive antitumor activity of pf-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-met, in experimental models of anaplastic large-cell lymphoma. Mol. Cancer Ther. 2007, 6, 3314–3322. [Google Scholar] [CrossRef]
- Xu, H.; Stabile, L.P.; Gubish, C.T.; Gooding, W.E.; Grandis, J.R.; Siegfried, J.M. Dual blockade of egfr and c-met abrogates redundant signaling and proliferation in head and neck carcinoma cells. Clin. Cancer Res. 2011, 17, 4425–4438. [Google Scholar] [CrossRef]
- Qian, F.; Engst, S.; Yamaguchi, K.; Yu, P.; Won, K.A.; Mock, L.; Lou, T.; Tan, J.; Li, C.; Tam, D.; et al. Inhibition of tumor cell growth, invasion, and metastasis by exel-2880 (xl880, gsk1363089), a novel inhibitor of hgf and vegf receptor tyrosine kinases. Cancer Res. 2009, 69, 8009–8016. [Google Scholar] [CrossRef]
- Yan, S.B.; Peek, V.L.; Ajamie, R.; Buchanan, S.G.; Graff, J.R.; Heidler, S.A.; Hui, Y.H.; Huss, K.L.; Konicek, B.W.; Manro, J.R.; et al. Ly2801653 is an orally bioavailable multi-kinase inhibitor with potent activity against met, mst1r, and other oncoproteins, and displays anti-tumor activities in mouse xenograft models. Invest. New Drugs 2013, 31, 833–844. [Google Scholar] [CrossRef]
© 2013 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).
Share and Cite
Xu, Y.; Fisher, G.J. Role of Met Axis in Head and Neck Cancer. Cancers 2013, 5, 1601-1618. https://doi.org/10.3390/cancers5041601
Xu Y, Fisher GJ. Role of Met Axis in Head and Neck Cancer. Cancers. 2013; 5(4):1601-1618. https://doi.org/10.3390/cancers5041601
Chicago/Turabian StyleXu, Yiru, and Gary J. Fisher. 2013. "Role of Met Axis in Head and Neck Cancer" Cancers 5, no. 4: 1601-1618. https://doi.org/10.3390/cancers5041601